Kiniksa Pharmaceuticals International Management
Management Kriterienprüfungen 4/4
Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.
Wichtige Informationen
Sanj Patel
Geschäftsführender
US$5.3m
Gesamtvergütung
| Prozentsatz des Geschäftsführergehalts | 16.3% |
| Amtszeit als Geschäftsführer | 9yrs |
| Eigentum des Geschäftsführers | 2.4% |
| Durchschnittliche Amtszeit des Managements | 3.5yrs |
| Durchschnittliche Amtszeit der Vorstandsmitglieder | 7.6yrs |
Jüngste Management Updates
Recent updates
Kiniksa Pharmaceuticals, Ltd.'s (NASDAQ:KNSA) Share Price Is Matching Sentiment Around Its Revenues
Jun 19
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
Apr 25Kiniksa Pharmaceuticals: Arcalyst Performs While Abiprubart Plans Take Shape
Apr 24Kiniksa Pharmaceuticals, Ltd. Just Reported A Surprise Profit And Analysts Updated Their Estimates
Mar 01We're Not Worried About Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn
Feb 28The Market Doesn't Like What It Sees From Kiniksa Pharmaceuticals, Ltd.'s (NASDAQ:KNSA) Revenues Yet
Dec 18We're Interested To See How Kiniksa Pharmaceuticals (NASDAQ:KNSA) Uses Its Cash Hoard To Grow
Nov 10Investors Don't See Light At End Of Kiniksa Pharmaceuticals, Ltd.'s (NASDAQ:KNSA) Tunnel
Apr 18Investors Shouldn't Be Too Comfortable With Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Robust Earnings
Nov 10Industry Analysts Just Upgraded Their Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Revenue Forecasts By 27%
Aug 04Kiniksa Pharmaceuticals GAAP EPS of -$0.29 beats by $0.15, revenue of $26.97M misses by $1.58M, reaffirms FY revenue guidance
Aug 03Analysts Are Updating Their Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Estimates After Its First-Quarter Results
May 05We're Keeping An Eye On Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn Rate
Mar 18Kiniksa: Latest Earnings Beat Shows Light At The End Of The Tunnel
Nov 25Is Kiniksa Pharmaceuticals (NASDAQ:KNSA) A Risky Investment?
Nov 04Kiniksa: Unexciting, Slow Growth Stock
Aug 13We're Keeping An Eye On Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn Rate
Jul 31Kiniksa outlines development path for mavrilimumab after FDA feedback
Jun 08Kiniksa: A Look At Mavrilimumab
May 03Here's Why We're Not Too Worried About Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn Situation
Apr 17What Kind Of Investors Own Most Of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)?
Jan 02
Kiniksa's antibody treatment shows clinical benefit in late-stage COVID-19 study
Dec 22Dosing underway in Kiniksa Pharma's lumpy skin disease study with vixarelimab
Dec 15Kiniksa Pharma's KPL-404 shows encouraging action in early-stage study
Nov 30Kiniksa's vixarelimab nabs accelerated review in U.S. for a skin disorder
Nov 16Analyse der Geschäftsführervergütung
| Datum | Gesamtvergütung | Gehalt | Unternehmensgewinne |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | US$9m |
| Dec 31 2023 | US$5m | US$864k | US$14m |
| Sep 30 2023 | n/a | n/a | -US$7m |
| Jun 30 2023 | n/a | n/a | US$231m |
| Mar 31 2023 | n/a | n/a | US$196m |
| Dec 31 2022 | US$6m | US$835k | US$183m |
| Sep 30 2022 | n/a | n/a | US$143m |
| Jun 30 2022 | n/a | n/a | -US$112m |
| Mar 31 2022 | n/a | n/a | -US$134m |
| Dec 31 2021 | US$7m | US$803k | -US$158m |
| Sep 30 2021 | n/a | n/a | -US$175m |
| Jun 30 2021 | n/a | n/a | -US$189m |
| Mar 31 2021 | n/a | n/a | -US$184m |
| Dec 31 2020 | US$5m | US$780k | -US$161m |
| Sep 30 2020 | n/a | n/a | -US$140m |
| Jun 30 2020 | n/a | n/a | -US$123m |
| Mar 31 2020 | n/a | n/a | -US$122m |
| Dec 31 2019 | US$5m | US$780k | -US$162m |
| Sep 30 2019 | n/a | n/a | -US$173m |
| Jun 30 2019 | n/a | n/a | -US$170m |
| Mar 31 2019 | n/a | n/a | -US$153m |
| Dec 31 2018 | US$7m | US$740k | -US$103m |
| Sep 30 2018 | n/a | n/a | -US$93m |
| Jun 30 2018 | n/a | n/a | -US$85m |
| Mar 31 2018 | n/a | n/a | -US$76m |
| Dec 31 2017 | US$1m | US$700k | -US$65m |
Vergütung im Vergleich zum Markt: SanjDie Gesamtvergütung ($USD5.30M) liegt im Durchschnitt der Unternehmen ähnlicher Größe auf dem Markt US ($USD5.67M).
Entschädigung vs. Einkommen: SanjDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.
Geschäftsführer
Sanj Patel (55 yo)
9yrs
Amtszeit
US$5,297,067
Vergütung
Mr. Sanj K. Patel has been the Chief Executive Officer of Kiniksa Pharmaceuticals International, plc (formerly known as Kiniksa Pharmaceuticals, Ltd.) since July 2015. Before founding Kiniksa Pharmaceutica...
Führungsteam
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| CEO & Chairman of the Board | 9yrs | US$5.30m | 2.39% $ 32.5m | |
| Senior VP & COO | 2.5yrs | US$1.75m | 0.18% $ 2.4m | |
| Senior VP & Chief Medical Officer | 7.9yrs | US$1.79m | 0.067% $ 913.0k | |
| Senior VP & CFO | 3.6yrs | keine Daten | 0.027% $ 367.8k | |
| Chief Accounting Officer & Group VP of Finance | 4.4yrs | keine Daten | 0.030% $ 407.3k | |
| Senior Vice President of Technical Operations | 3.5yrs | keine Daten | keine Daten | |
| Senior Director of Investor Relations & Corporate Communications | no data | keine Daten | keine Daten | |
| Senior VP & Chief Compliance Officer | 3.3yrs | keine Daten | keine Daten | |
| SVP, General Counsel & Secretary | 3.5yrs | keine Daten | keine Daten | |
| Executive Vice President of Corporate Affairs | no data | keine Daten | keine Daten | |
| Senior Vice President of Regulatory Affairs | 3.6yrs | keine Daten | keine Daten | |
| Senior VP & Chief Commercial Officer | 2.5yrs | keine Daten | 0.023% $ 310.9k |
3.5yrs
Durchschnittliche Betriebszugehörigkeit
51.5yo
Durchschnittliches Alter
Erfahrenes Management: KNSADas Führungsteam des Unternehmens gilt als erfahren (3.5 Jahre durchschnittliche Betriebszugehörigkeit).
Vorstandsmitglieder
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| CEO & Chairman of the Board | 9yrs | US$5.30m | 2.39% $ 32.5m | |
| Independent Director | 6.4yrs | US$362.66k | 0.013% $ 179.1k | |
| Lead Independent Director | 8.8yrs | US$411.06k | 0.028% $ 378.9k | |
| Independent Director | 7.6yrs | US$380.36k | 0.013% $ 179.1k | |
| Independent Director | 8.8yrs | US$372.55k | 0.013% $ 179.1k | |
| Independent Director | 5.3yrs | US$459.75k | 0.018% $ 246.3k | |
| Independent Director | 4yrs | US$365.36k | 0.013% $ 179.1k | |
| Independent Director | 8.8yrs | US$371.96k | 0.0070% $ 95.4k | |
| Chairman of Scientific Advisory Board | no data | keine Daten | 2.08% $ 28.2m | |
| Independent Director | 6.4yrs | US$365.36k | 0.013% $ 179.1k |
7.6yrs
Durchschnittliche Betriebszugehörigkeit
56yo
Durchschnittliches Alter
Erfahrener Vorstand: KNSADie Vorstandsmitglieder gelten als erfahren (7.5 Jahre durchschnittliche Amtszeit).